Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-09-18
2007-09-18
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S192100, C424S203100, C424S190100, C424S184100, C514S002600, C530S350000, C530S300000, C530S825000, C530S806000
Reexamination Certificate
active
10284400
ABSTRACT:
Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.
REFERENCES:
patent: 4284537 (1981-08-01), Beachey
patent: 4399216 (1983-08-01), Axel et al.
patent: 4411993 (1983-10-01), Gillis
patent: 4454121 (1984-06-01), Beachey
patent: 4460575 (1984-07-01), d'Hinterland et al.
patent: 4521334 (1985-06-01), Beachey
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: RE32011 (1985-10-01), Zimmerman et al.
patent: 4579821 (1986-04-01), Palmiter et al.
patent: 4597967 (1986-07-01), Beachey
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4705684 (1987-11-01), Beachey
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 4784948 (1988-11-01), Scott et al.
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4801542 (1989-01-01), Murray et al.
patent: 4902614 (1990-02-01), Wakabayashi et al.
patent: 4919930 (1990-04-01), Beachey et al.
patent: 4935349 (1990-06-01), McKnight et al.
patent: 4987071 (1991-01-01), Cech et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5162226 (1992-11-01), Beachey et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5254678 (1993-10-01), Haseloff et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5359051 (1994-10-01), Cook et al.
patent: 5443439 (1995-08-01), Ohshita
patent: 5580563 (1996-12-01), Tam
patent: 5686272 (1997-11-01), Marshall et al.
patent: 5726292 (1998-03-01), Lowell
patent: 5985284 (1999-11-01), Lowell
patent: 5985654 (1999-11-01), Fischetti et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6419932 (2002-07-01), Dale
patent: 6716433 (2004-04-01), Dale
patent: 7063850 (2006-06-01), Dale
patent: 7074416 (2006-07-01), Dale
patent: 2002/0176863 (2002-11-01), Dale
patent: 612 844 (1994-08-01), None
patent: 305279 (1995-03-01), None
patent: 360 257 (1996-11-01), None
patent: 618813 (2002-01-01), None
patent: 625043 (2002-03-01), None
patent: 415 731 (2003-04-01), None
patent: WO90/07936 (1990-07-01), None
patent: WO91/02805 (1991-03-01), None
patent: WO92/06693 (1992-04-01), None
patent: WO93/10218 (1993-05-01), None
patent: WO93/11230 (1993-06-01), None
patent: WO93/25234 (1993-12-01), None
patent: WO93/25698 (1993-12-01), None
patent: WO94/03622 (1994-02-01), None
patent: WO94/06421 (1994-03-01), None
patent: WO94/06465 (1994-03-01), None
patent: WO94/26914 (1994-11-01), None
patent: WO95/10607 (1995-04-01), None
patent: WO98/01561 (1998-01-01), None
patent: WO99/13084 (1999-03-01), None
patent: WO 00/37648 (2000-06-01), None
Alan L. Bisno, “The Concept of Rheumatogenic and Nonrheumatogenic Group A Streptococci,” inStreptococcal Diseases and the Immune Response, New York: Academic Press, 1980, pp. 789-803.
Beachey and Seyer, “Protective and nonprotective epitopes of chemically synthesized peptides of the NH2-terminal region of type 6 streptococcal M protein,”Journal of Immunology 136(6): 2287-2292, Mar. 15, 1986.
Beachey, E. et al., “Human Immune Response to Immunization with a Structurally Defined Polypeptide Fragment of Streptococcal M Protein,”Journal of Experimental Medicine 150: 862-877, Oct. 1979.
Beachey, E.H. et al., “Primary Structure of Protective Antigens of Type 24 Streptococcal M Protein,”The Journal of Biological Chemistry 255(13): 6284-6289, Jul. 10, 1980.
Beachey, E.H. et al., “Protective Immunogenicity and T Lymphocyte Specificity of a Trivalent Hybrid Peptide Containing NH2-Terminal Sequences of Types 5, 6, and 24 M Proteins Synthesized in Tandem,”Journal of Experimental Medicine 166: 647-656, Sep. 1987.
Beachey, E.H. et al., “Purification and Properties of M Protein Extracted From Group A Streptococci With Pepsin: Covalent Structure of the Amino Terminal Region of Type 24 M Antigen,”Journal of Experimental Medicine 145: 1469-1483, 1977.
Beachey, E.H. et al., “Repeating Covalent Structure and Protective Immunogenicity of Native and Synthetic Polypeptide Fragments of Type 24 Streptococcal M Protein,”The Journal of Biological Chemistry 258(21):13250-13257, Nov. 10, 1983.
Beachey, E.H. et al., “Type-specific protective immunity evoked by synthetic peptide ofStreptococcus pyogenesM protein,”Nature 292: 457-459, Jul. 30, 1981.
Beall, B. et al., “Survey ofemmGene Sequences and T-Antigen Types from SystemicStreptococcus pyogenesInfection Isolates Collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995,”Journal of Clinical Microbiology 35(5): 1231-1235, May 1997.
Boyle, M.D. et al., “Role ofemmandmrpgenes in the virulence of group A streptococcal isolate 64/14 in a mouse model of skin infection,”J. Infect. Dis. 177(4): 991-997, Apr. 1998.
Bronze, M.S. et al., “Protective and Heart-Cross Reactive Epitopes Located Within the NH2Terminus of Type of 19 Streptococcal M Protein,”Journal of Experimental Medicine 167: 1849-1859, Jun. 1988.
Bronze, M.S. et al., “Protective and heart-cross-reactive epitopes of type 19 streptococcal M protein,”Trans. Assoc. Am. Physicians 100: 80-84, 1987.
Clements and El-Morshidy, “Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas,”Infect. Immun. 46(2): 564-569, Nov. 1984.
Clements, J.D., “Construction of a Nontoxic Fusion Peptide for Immunization againstEscherichia coliStrains That Produce Heat-Labile and Heat-Stable Enterotoxins,”Infect. Immun. 58(5): 1159-1166, May 1990.
Cunningham M.W. et al., Peptic Digestion of Streptococcal M Protein. I. Effect of Digestion at Suboptimal pH upon the Biological and Immunochemical Purified M Protein Extracts,Infection and Immunity 9(2): 244-248, Feb. 1974.
Cunningham, M.W., “Pathogenesis of Group A Streptococcal Infections,”Clinical Microbiology Reviews 13(3): 470-511, Jul. 2000.
Dale and Beachey, “Epitopes of Streptococcal M Proteins Shared with Cardiac Myosin,”Journal of Experimental Medicine 162: 583-591, Aug. 1985.
Dale and Beachey, “Localization of Protective Epitopes of the Amino Terminus of Type 5 Streptococcal M Protein,”Journal of Experimental Medicine 163: 1191-1202, May 1986.
Dale and Beachey, “Multiple, Heart-Cross-Reactive Epitopes of Streptococcal M Proteins,”Journal of Experimental Medicine 161: 113-122, Jan. 1985.
Dale and Beachey, “Sequence of Myosin-Crossreactive Epitopes of Streptococcal M Protein,”Journal of Experimental Medicine 164: 1785-1790, Nov. 1986.
Dale, J.B. et al. “Heterogeneity of type-specific and cross-reactive antigenic determinants within a single M protein of group A streptococci,”Journal of Experimental Medicine 151: 1026-1038, 1980.
Dale, J.B. et al., “New protective antigen of group A streptococci,”Journal of Clinical Investigation 103(9): 1261-1268, May 1999.
Dale, J.B. et al., “Protective Antigenic Determinant of Streptococcal M Protein Shared with Sarcolemmal Membrane Protein of Human Heart,”Journal of Experimental Medicine 156(4): 1165-1176, Oct. 1982.
Dale, J.B. et al., “Recombinant Tetravalent Group A Streptococcal M Protein Vaccine,”Journal of Immunology 151(4): 2188-2194, Aug. 15, 1993.
Dale, J.B. et al., “Recombinant, octavalent group A streptococcal M protein vaccine,”Vaccine 14(10): 944-948, Jul. 1996.
Dale, J.B. et al., “Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein,”Journal of Experimental Medicine 158: 1727-1732, Nov. 1983
Dale James B.
Hu Mary ChaoHong
Reddish Mark A.
Walls Michael A.
Devi S.
ID Biomedical Corporation of Washington
Seed IP Law Group PLLC
University of Tennessee Research Foundation
LandOfFree
Multivalent streptococcal vaccine compositions and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent streptococcal vaccine compositions and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent streptococcal vaccine compositions and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3756348